Jan 20 (Reuters) - Britain's GSK will buy RAPT Therapeutics for $2.2 billion, adding global rights to the U.S. firm's ...
GSK has agreed to acquire RAPT Therapeutics, adding food allergy drug candidates to its pipeline. The company has received ...
The drugmaker said it agreed to pay RAPT Therapeutics shareholders $58 per share, with $1.9 billion upfront investment in ...
By Pushkala Aripaka and Bhanvi Satija Jan 20 (Reuters) - Britain's GSK has agreed to buy RAPT Therapeutics for $2.2 billion, ...
GlaxoSmithKline (GSK) announced an update on their ongoing clinical study.
That price equates to an aggregate equity value of $2.2 billion, according to GSK, who added that the upfront investment net ...
The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms ...
With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...
The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, ...
By Andrew MacAskill, Maggie Fick and Bhanvi Satija LONDON, Jan 26 (Reuters) - UK-based drugmakers AstraZeneca and GSK will ...
The growing scourge of food allergies drove U.K. heavyweight GSK to announce a $2.2 billion deal on Tuesday.
The European Commission has approved GSK’s respiratory syncytial virus (RSV) vaccine for use in all adults, the drugs giant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results